Related Experiment Video
Updated: Jul 13, 2026

Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
Cerebrospinal fluid biomarkers associated with neurofilament light levels: A study in HIV disease
Enrico Ripamonti1, Magnus Gisslén2, Lars Hagberg3
1Milan Center for Neuroscience, University of Milan-Bicocca, Milan, Italy; Department of Economics and Management, University of Brescia, Brescia, Italy.
Background:
A retrospective study was conducted in people with HIV (PWH) to explore potential cerebrospinal fluid (CSF) biomarkers linked to CSF neurofilament light levels (NfL), indicative of neuronal injury.
Methods:
A sample of 168 participants was tested, including 43 HIV-negative controls and PWH who were classified into subgroups based on HIV and treatment status. Twenty CSF protein biomarkers were analyzed for their association with CSF NfL concentrations using a linear regression forward selection strategy, adjusted for age and sex. Regression trees were utilized to visualize feature relationships.
Results:
Age-adjusted average concentrations of CSF NfL ranged from 427 pg/mL (SD = 190) in HIV- participants to 6456 pg/mL (SD = 46,024) in participants with HIV-associated dementia. Significant associations were found between specific biomarkers and CSF NfL levels in different participant subgroups. Noteworthy findings included correlations between CSF t-tau, CSF MCP-1, CSF TNF-α, and albumin ratio with CSF NfL levels in untreated PWH, and CSF IL-21 with CSF NfL in treated, virally suppressed PWH. Association between age and CSF NfL concentrations was a general finding.
Conclusion:
We identified specific CSF biomarkers, including CSF t-tau protein, CSF MCP-1, and CSF TNF-α that associated with CSF NfL concentrations in untreated PWH and CSF IL-21 that associated with CSF NfL in PWH with effective treatment, shedding light on neuroinflammatory processes which may underlie HIV-related neuronal injury and the impact of antiviral therapy. Further investigations are needed to validate if elevated CSF IL-21 concentrations persist during long-term treatment, and if particular drug combinations are optimal for decreasing inflammatory latency.

